Cell therapy company Chimeric Therapeutics (ASX:CHM) has provided additional information on its previously announced positive in vitro data for CHM 1301.
-
Latest News Chimeric Therapeutics provides additional information on vitro data for CHM 1301 November 30, 2023
-
Latest News Microba completes stage one screening for its autoimmune disease program November 30, 2023Microba Life Sciences (ASX:MAP) has announced that stage one activity screening for its autoimmune disease program has been completed on schedule with partner Ginkgo Bioworks.
-
Latest News Medical science a 'priority area' for new Industry Growth Program November 28, 2023The Albanese Government has officially opened the $392 million Industry Growth Program that includes medical science as one of its priority target areas.
-
AusBiotech AusBiotech weighs in on Australia’s RNA future November 28, 2023AusBiotech has urged policy-makers to take a national approach to capability mapping and introduce targeted initiatives in response to the federal government’s discussion paper, Understanding our RNA potential.
-
Latest News Dimerix's ACTION3 investigational new drug approved in China November 28, 2023Dimerix (ASX:DXB) has announced that Chinese National Medical Products Administration Center for Drug Evaluation has approved an Investigational New Drug application to commence recruitment for ACTION3 Phase 3 study of DMX-200 for focal segmental glomerulosclerosis kidney disease.
-
Latest News Federal government backs the development of treatment for childhood brain cancer November 28, 2023Health Minister Mark Butler has announced that the federal government will invest over $700,000 to support the development of a potential new treatment that targets a type of childhood brain cancer with no known cure or treatment options.
-
Latest News Island Pharmaceuticals doses first cohort in ISLA-101 study November 28, 2023Australian antiviral drug development company Island Pharmaceuticals (ASX:ILA) has dosed the first cohort in its single ascending dose study for ISLA-101.
-
Latest News The Cell and Gene Catalyst call for change in submission to scope of practice review November 23, 2023The Australian Cell & Gene Catalyst has issued its response to the federal government's health workforce scope of practice review.
-
AusBiotech Antimicrobial resistance highlighted in global campaign November 23, 2023AMR is an increasing global health priority, estimated to be directly responsible for 1.27 million deaths worldwide in 2019.
-
Latest News Race Oncology announces the appointment of new chief executive November 23, 2023Australian company Race Oncology (ASX:RAC) has announced the appointment of Dr Daniel Tillett as its new chief executive officer.
-
Latest News Successful clinical trial for re-engineered UQ vaccine November 23, 2023The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved vaccine.
-
Latest News Alterity Therapeutics raises $4.8 million in new placement November 23, 2023Alterity Therapeutics (ASX:ATH) has received binding commitments for a capital raising of $4.8 million before costs via a two-tranche placement of fully paid ordinary shares to Australian and international institutions and other unrelated sophisticated, professional or other exempt investors.
-
Latest News Orthocell announces final positive results of cell therapy in 'tennis elbow' study November 21, 2023Orthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoATI to surgery to treat severe, chronic, treatment-resistant lateral epicondylitis.
-
AusBiotech Best early-stage projects awarded at AusBiotech 2023 November 21, 2023QIMR Berghofer and Murdoch University researchers were announced as joint winners at AusBiotech 2023’s Early-Stage Innovation Forum held in Brisbane on 3 November.
-
Latest News Chimeric Therapeutics announces presentation of trial at major US meeting November 21, 2023Australian cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the ADVENT-AML Phase 1B clinical trial abstract was selected for presentation at the 2023 Annual Meeting of the American Society of Hematology.
-
Latest News Anteris reports positive 30-Day haemodynamic results from trial November 21, 2023Anteris Technologies (ASX:AVR) has reported 30-day data from the US Early Feasibility Study for DurAVR Transcatheter Heart Valve.
-
Latest News 4DMedical receives US FDA clearance for its CT-based ventilation product November 21, 2023Respiratory imaging technology company 4DMedical Limited (ASX:4DX) has US FDA-received clearance for its CT-based ventilation product.
New Stories
-
National Reconstruction Fund investment mandate released
November 30, 2023 - - AusBiotech -
Clarity’s theranostic prostate cancer trial progresses at the highest dose level cohort
November 30, 2023 - - Latest News -
4DMedical and Philips sign Memorandum of Understanding
November 30, 2023 - - Latest News -
Chimeric Therapeutics provides additional information on vitro data for CHM 1301
November 30, 2023 - - Latest News -
Microba completes stage one screening for its autoimmune disease program
November 30, 2023 - - Latest News -
AusBiotech weighs in on Australia’s RNA future
November 28, 2023 - - AusBiotech -
Federal government backs the development of treatment for childhood brain cancer
November 28, 2023 - - Latest News